Inclusion Criteria:
  -  Molecular confirmation of a pathogenic or likely pathogenic PCDH19 variant
  -  Failure to control seizures despite 2 or more anti-seizure medications
  -  12 seizures over a 12-week period of primary seizure types prior to screening
  -  On a stable regimen of anti-seizure treatments (Vagus nerve stimulator, ketogenic diet, and modified Atkins diet should be unchanged for 3 months prior to screening)
Exclusion Criteria:
  -  Previous exposure to ganaxolone
  -  > 8 consecutive weeks of seizure freedom during the 12 weeks prior to screening
  -  Concurrent use of strong inducers or inhibitors of CYP3A4/5/7 is not permitted
  -  Use of tetrahydrocannabinol (THC) or non-approved cannabidiol (CBD) is prohibited during the double-blind phase
  -  Exposure to any other investigational drug within 30 days or fewer than 5 half-lives prior to screening